Myelin is crucial for the correct functioning of nerve signaling and its loss is a feature of neurological disorders. The cells responsible for myelination in the CNS are oligodendrocytes (OLs), which derive from oligodendrocyte precursor cells (OPCs).

Mira Pharmaceuticals Inc. has reported results from preclinical studies evaluating an optimized oral formulation of SKNY-1, an oral drug candidate being developed for obesity and addiction-related disorders.

In a recent study, researchers from Washington University School of Medicine and collaborators analyzed cross-sectional blood samples to identify circRNAs associated with Alzheimer’s disease (AD) clinical status, amyloid-β and tau stages, and progression to symptomatic AD.

Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device, which can reduce their symptoms in as little as four weeks. The treatment, designed for at-home use of 30-minute daily sessions, was approved for use within the Department of Veterans Affairs after the company secured FDA de novo approval.

The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly, researchers are suspecting that such epilepsies share mechanisms with dementia. Summarizing the highlights of epilepsy research presented at the recent Annual Congress of the European Academy of Neurology (EAN), Aleksandar Ristic told his audience that the biggest epilepsy story out of the Congress was “not a drug, but it was a reframing.”

In Alzheimer’s disease (AD), 17β-HSD10 and CDK5/p25 contribute to neuronal dysfunction through distinct but interconnected pathways involving mitochondrial impairment and tau-mediated neurodegeneration, supporting their potential as complementary therapeutic targets.

Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company, months after winning approval for the country’s first invasive BCI system.